Integrated multimodal cell atlas of Alzheimer's disease.
Gabitto MI, Travaglini KJ, Rachleff VM, Kaplan ES, Long B, Ariza J, Ding Y, Mahoney JT, Dee N, Goldy J, Melief EJ, Agrawal A, Kana O, Zhen X, Barlow ST, Brouner K, Campos J, Campos J, Carr AJ, Casper T, Chakrabarty R, Clark M, Cool J, Dalley R, Darvas M, Ding SL, Dolbeare T, Egdorf T, Esposito L, Ferrer R, Fleckenstein LE, Gala R, Gary A, Gelfand E, Gloe J, Guilford N, Guzman J, Hirschstein D, Ho W, Hupp M, Jarsky T, Johansen N, Kalmbach BE, Keene LM, Khawand S, Kilgore MD, Kirkland A, Kunst M, Lee BR, Leytze M, Mac Donald CL, Malone J, Maltzer Z, Martin N, McCue R, McMillen D, Mena G, Meyerdierks E, Meyers KP, Mollenkopf T, Montine M, Nolan AL, Nyhus JK, Olsen PA, Pacleb M, Pagan CM, Peña N, Pham T, Pom CA, Postupna N, Rimorin C, Ruiz A, Saldi GA, Schantz AM, Shapovalova NV, Sorensen SA, Staats B, Sullivan M, Sunkin SM, Thompson C, Tieu M, Ting JT, Torkelson A, Tran T, Valera Cuevas NJ, Walling-Bell S, Wang MQ, Waters J, Wilson AM, Xiao M, Haynor D, Gatto NM, Jayadev S, Mufti S, Ng L, Mukherjee S, Crane PK, Latimer CS, Levi BP, Smith KA, Close JL, Miller JA, Hodge RD, Larson EB, Grabowski TJ, Hawrylycz M, Keene CD, Lein ES. · 2024
Read Integrated multimodal cell atlas of Alzheimer's disease. by Gabitto MI, Travaglini KJ, Rachleff VM, Kaplan ES, Long B, Ariza J, Ding Y, Mahoney JT, Dee N, Goldy J, Melief EJ, Agrawal A, Kana O, Zhen X, Barlow ST, Brouner K, Campos J, Campos J, Carr AJ, Casper T, Chakrabarty R, Clark M, Cool J, Dalley R, Darvas M, Ding SL, Dolbeare T, Egdorf T, Esposito L, Ferrer R, Fleckenstein LE, Gala R, Gary A, Gelfand E, Gloe J, Guilford N, Guzman J, Hirschstein D, Ho W, Hupp M, Jarsky T, Johansen N, Kalmbach BE, Keene LM, Khawand S, Kilgore MD, Kirkland A, Kunst M, Lee BR, Leytze M, Mac Donald CL, Malone J, Maltzer Z, Martin N, McCue R, McMillen D, Mena G, Meyerdierks E, Meyers KP, Mollenkopf T, Montine M, Nolan AL, Nyhus JK, Olsen PA, Pacleb M, Pagan CM, Peña N, Pham T, Pom CA, Postupna N, Rimorin C, Ruiz A, Saldi GA, Schantz AM, Shapovalova NV, Sorensen SA, Staats B, Sullivan M, Sunkin SM, Thompson C, Tieu M, Ting JT, Torkelson A, Tran T, Valera Cuevas NJ, Walling-Bell S, Wang MQ, Waters J, Wilson AM, Xiao M, Haynor D, Gatto NM, Jayadev S, Mufti S, Ng L, Mukherjee S, Crane PK, Latimer CS, Levi BP, Smith KA, Close JL, Miller JA, Hodge RD, Larson EB, Grabowski TJ, Hawrylycz M, Keene CD, Lein ES. (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc11614693.txt.
Introduction
Gabitto and a very large team build an integrated cell atlas of Alzheimer disease in this 2024 study. Alzheimer disease is the top cause of dementia in older adults. Its progression follows a stereotyped accumulation of protein deposits, but the affected cell populations remained understudied. The team applied multiomics and spatial genomics to one brain region, the middle temporal gyrus, in 84 donors.
Donors averaged 88 years at death and were scored along a disease pseudoprogression scale. Two phases emerged, they report. An early phase showed slow pathology growth, inflammatory microglia, reactive astrocytes, and loss of one inhibitory neuron type. Precursor cells attempted remyelination, meaning repair of nerve insulation. A later phase showed exponential pathology growth and loss of excitatory neurons plus two more inhibitory subtypes. The findings were replicated in other major Alzheimer studies.
Catalog record
| CREATOR | Gabitto MI, Travaglini KJ, Rachleff VM, Kaplan ES, Long B, Ariza J, Ding Y, Mahoney JT, Dee N, Goldy J, Melief EJ, Agrawal A, Kana O, Zhen X, Barlow ST, Brouner K, Campos J, Campos J, Carr AJ, Casper T, Chakrabarty R, Clark M, Cool J, Dalley R, Darvas M, Ding SL, Dolbeare T, Egdorf T, Esposito L, Ferrer R, Fleckenstein LE, Gala R, Gary A, Gelfand E, Gloe J, Guilford N, Guzman J, Hirschstein D, Ho W, Hupp M, Jarsky T, Johansen N, Kalmbach BE, Keene LM, Khawand S, Kilgore MD, Kirkland A, Kunst M, Lee BR, Leytze M, Mac Donald CL, Malone J, Maltzer Z, Martin N, McCue R, McMillen D, Mena G, Meyerdierks E, Meyers KP, Mollenkopf T, Montine M, Nolan AL, Nyhus JK, Olsen PA, Pacleb M, Pagan CM, Peña N, Pham T, Pom CA, Postupna N, Rimorin C, Ruiz A, Saldi GA, Schantz AM, Shapovalova NV, Sorensen SA, Staats B, Sullivan M, Sunkin SM, Thompson C, Tieu M, Ting JT, Torkelson A, Tran T, Valera Cuevas NJ, Walling-Bell S, Wang MQ, Waters J, Wilson AM, Xiao M, Haynor D, Gatto NM, Jayadev S, Mufti S, Ng L, Mukherjee S, Crane PK, Latimer CS, Levi BP, Smith KA, Close JL, Miller JA, Hodge RD, Larson EB, Grabowski TJ, Hawrylycz M, Keene CD, Lein ES. |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 131 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Integrated multimodal cell atlas of Alzheimer’s disease By Mariano I. Gabitto, Kyle J. Travaglini, Victoria M. Rachleff, Eitan S. Kaplan, Brian Long, Jeanelle Ariza, Yi Ding, Joseph T. Mahoney, Nick Dee, Jeff Goldy, Erica J. Melief, Anamika Agrawal Published in: Nature Neuroscience DOI: 10.1038/s41593-024-01774-5 ABSTRACT Alzheimer’s disease (AD) is the leading cause of dementia in older adults. Although AD progression is characterized by stereotyped accumulation of proteinopathies, the affected cellular populations remain understudied. Here we use multiomics, spatial genomics and reference atlases from the BRAIN Initiative to study middle temporal gyrus cell types in 84 donors with varying AD pathologies. This cohort includes 33 male donors and 51 female donors, with an average age at time of death of 88 years. We used quantitative neuropathology to place donors along a disease pseudoprogression score. Pseudoprogression analysis revealed two disease phases: an early phase with a slow increase in pathology, presence of inflammatory microglia, reactive astrocytes, loss of somatostatin+ inhibitory neurons, and a remyelination response by oligodendrocyte precursor cells; and a later phase with exponential increase in pathology, loss of excitatory neurons and Pvalb+ and Vip+ inhibitory neuron subtypes. These findings were replicated in other major AD studies. MAIN Alzheimer’s disease (AD) is characterized by deposition of hallmark pathological peptides and neurodegeneration that progress across partially overlapping neuroanatomical and temporal axes1,2. This process is generally believed to follow a stereotyped progression with amyloid beta (Aβ) plaques starting in the cerebral cortex3 and hyperphosphorylated Tau (pTau) aggregation (neurofibrillary tangles (NFTs)) starting in the brainstem and limbic system4. Single-cell and spatial genomics technologies now offer a dramatically higher-resolution analysis of complex brain tissues; multiple studies have now begun to apply them to identify cellular vulnerabilities and molecular changes with AD5–15. Recent work catalyzed by the BRAIN Initiative Cell Census Network (BICCN) and BRAIN Initiative Cell Atlas Network (BICAN) has established best practices in experimental and quantitative analyses to harness single-cell genomics, spatial transcriptomics and patch sequencing (patch-seq) methods to characterize cellular properties and build a knowledge base of brain cell types16–22. Systematic BICCN and BICAN efforts are now producing the first brain-wide cell atlases of the mouse23 and human brain17–19, providing robust and highly curated, genomically based reference cell classifications, spatial maps of cellular distributions, and characterization of cellular properties in the normal brain. These reference classifications provide an extremely powerful foundational reference to understand the cellular, molecular and epigenomic underpinnings of AD. Furthermore, mapping to this reference allows integration across data modalities and across independent studies to validate findings and leverage a growing knowledge base on the properties and function of cell types that are affected in disease. The Seattle Alzheimer’s Disease Brain Cell Atlas (SEA-AD) consortium aims to use these advances to produce the highest-resolution, multimodal, brain-wide cell atlas of AD and related dementias mapped to the BICCN foundational references. Keys to achieving this goal are: (1) a high-quality donor cohort spanning the full spectrum of AD pathology (instead of a case-control design), recruited from longitudinal cohort studies with well-characterized participants; (2) the use of improved tissue preparation methods for single-nucleus and spatial genomics16–19,24; (3) deep donor characterization with all analytical methods applied to the same donors; (4) sufficient sampling to analyze the full diversity of cell types; (5) mapping profiled cells to the highly granular and curated BICCN cell type reference; and (6) validating cellular phenotypes across cortical areas, orthogonal modalities and independent datasets. The current study focused on the middle temporal gyrus (MTG), an area involved in language and semantic memory processing25 and higher-order visual processing26. Many studies, from the histopathology of Braak and Braak4 to longitudinal studies of Tau positron emission tomography imaging27,28, demonstrate that MTG is a transition zone between aging-related or preclinical AD-related medial temporal lobe pTau and more advanced stages of AD, where neocortical pTau extends across the brain and is strongly correlated with dementia4,29–31. By combining temporal modeling of disease severity based on quantitative neuropathology with single-nucleus genomics and spatial analyses, this approach provides a comprehensive understanding of the specific, highly granular cell types affected over the course of disease, where those affected cells are located in tissue microarchitecture and when they are affected as disease progresses. This strategy to integrate data across studies to a common reference is highly extensible and provides a unifying framework for the AD community. Study data are freely available at the SEA-AD’s website (https://portal.brain-map.org/explore/seattle-alzheimers-disease). RESULTS Profiling AD progression across pathological stages To construct an integrated multimodal cellular atlas of AD and comorbid related disorders (AD/AD and related dementias) we generated (1) quantitative neuropathological measurements, (2) single-nucleus RNA sequencing (snRNA-seq), single-nucleus assay for transposase-accessible chromatin with sequencing (snATAC–seq) and single-nucleus multiome (snMultiome), and (3) cellularly resolved spatial transcriptomics (multiplexed error-robust fluorescence in situ hybridization (MERFISH)) in the MTG from a cohort of 84 aged donors spanning the spectrum of AD pathology (Fig. 1a and Extended Data Fig. 1a). We collectively profiled 3.4 million high-quality nuclei across all modalities, mapping each to one of 139 molecular cell types from an expanded BRAIN Initiative MTG cellular taxonomy18 that included disease-associated states. A continuous pseudoprogression score (CPS) was constructed from quantitative neuropathology, which ordered donors along a neuropathological continuum, and increased discovery power to identify molecular and cellular changes. To validate and replicate these results, we generated a similar 1.2-million nuclei snRNA-seq dataset from Brodmann area 9 (A9) in the same 84 donors, mapping to a matched BRAIN Initiative A9 taxonomy. To replicate findings, we uniformly reprocessed ten publicly available datasets that applied snRNA-seq to 4.3 million high-quality nuclei from the prefrontal cortex (PFC), which includes the A9 of 707 additional donors also spanning the spectrum of AD pathology. These multimodal datasets, tools to explore them and tools to map new datasets to this new cellular taxonomy are all available at SEA-AD.Fig. 1SEA-AD study of the MTG and cohort description.a, Schematic detailing the experimental design for applying quantitative neuropathology, snRNA-seq, snATAC–seq, snMultiome and MERFISH to the MTG of SEA-AD donors. b, SEA-AD cohort demographics, depicting age at death, biological sex and APOE4 allele, stratified according to ADNC score. Age at death is represented by box-and-whisker plots with the box representing the interquartile range (IQR) and the whiskers representing 1.5 times the IQR. The solid line indicates the median. c, SEA-AD cohort composition stratified according to ADNC versus Braak stage Thal phase (left), and CERAD score as heatmaps, with dementia or comorbidities as bar plots. The number of donors in each box and the fraction are shown in parentheses. d, First PC for snRNA-seq versus snATAC–seq quality control metrics for each library color-coded according to ADNC category. The dashed red lines indicate the point where values are above 1.5 times the IQR. The gray line represents the linear regression (Pearson R = 0.80) e, The center lines represent the mean of the locally estimated scatter plot smoothing (LOESS) regression on longitudinal cognitive scores in the memory domain across ADNC 0–2 donors in gray, ADNC 3 donors in gold and ADNC 3 severely affected donors in purple. Uncertainty represents the s.e. from 1,000 LOESS fits with 80% of the data randomly selected in each iteration. f, Exemplar low-power and high-power micrographs showing the entire cortical column and cortical layers 3 and 5 from an ADNC3